STUDresearch · Non-peptide

Tongkat Ali

Also known as

Eurycoma longifolia · Eurycoma longifolia Jack · LJ100 · Physta · Longjack · Long Jack · Pasak Bumi · Malaysian ginseng (informal marketplace label) · Tongkat · TA (forum shorthand)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Some talk Systemic Oral Herbals in hormone discourse

Systemic oral root extract—HPG axis, stress-hormone, and whole-body vitality pathways, not a single local target.

What people say Tongkat ali is Eurycoma longifolia root extract, not one molecule. Products differ by extraction and markers such as eurycomanone, so equal milligrams need not mean equal exposure. Doses people talk about

Actual short community log400 mg once daily oral (3% extract)

One poster reported early GI effects then libido/energy changes across days 1–5; a later 800 mg empty-stomach report involved vomiting and is not a validated escalation.

Marker-strength discussion2% extracts often 200 mg; 10% extracts often 100 mg

Community product labels differ; equal milligrams do not imply equal eurycomanone or whole-extract exposure.

Physta trial arms100 mg or 200 mg once daily oral

Taken after breakfast for 12 weeks in the cited placebo-controlled design.

Rows preserve study, media and community examples—not a progression. A 3% 400 mg product, a 10% 100 mg product and a 200 mg trial extract are not interchangeable by capsule count.

Half-life & effect duration

Half-life in the body: Pure eurycomanone · IV · rats / miceAbout 18 minutes
Oral Tongkat extractNo settled estimate
Felt duration people report: Positive accountsChanges across days 1–5 or early weeks
Other accountsNo effect, digestive symptoms or delayed negative effects
One re-exposure accountNext-day brain fog lasting about 2 days

Timing context & sources

How it may feel Reports include no early change, GI upset, libido or energy, and delayed brain fog or joint pain. Same-author re-exposure accounts and multi-week trial outcomes do not produce one dependable per-dose feeling.

Cycles people discuss Human studies commonly use 4–12-week blocks, while community schedules range from continuous daily use to intermittent breaks. The evidence reviewed does not establish a superior cycling calendar. Timing Morning or AM/PM split use appears in community notes; evening use is often avoided when people feel wired, sleepless or irritable. Food timing varies: the Physta trial used after-breakfast dosing, while empty-stomach GI complaints appear in logs. These are schedules and tolerability reports, not a shared extract clock. Stacks Tongkat is discussed with fadogia, ashwagandha, cistanche, boron, zinc, magnesium and vitamin D. The detailed negative re-exposure report included many hormone, stimulant and supplement co-exposures, sharply limiting attribution. Watch for Not risk-free: Short-trial lab safety ≠ long-term high-dose multi-stack guarantee; product quality dominates real-world risk.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 0.30 hours after IV pure eurycomanone in rats and mice; not an oral Tongkat half-life.

Tables 1–2 place this estimate in the IV pure-compound groups, not the oral or extract groups.

Animal marker-compound PK cannot be directly extrapolated to a human whole-root product or used to set a human schedule.

Pharmacokinetics and bioavailability of eurycomanone in rodents (opens in a new tab)Tables 1–2, printed pages 7–8: 0.30 h is in the IV pure-eurycomanone groups; oral half-life cells are NA. Not a human whole-extract estimate.Rat/mouse marker-compound study; species and extract-matrix effects prevent conversion into a human whole-product half-life.

Felt duration people report

No dependable per-dose felt-duration window; positive, null, GI and delayed negative reports conflict.

One 3% 400 mg log described change across days 1–5. Another same-author history described positive early weeks and a later single re-exposure followed by next-day, roughly two-day brain fog amid many co-exposures.

Different extracts, unverified products, self-selection and extensive co-interventions; delayed symptoms do not measure parent persistence.

Tongkat Ali experience (opens in a new tab)OP and updates read: 3% extract at 400 mg/day; days 1–2 no clear effect except diarrhea/nausea, day 3 slight energy, days 4–5 higher libido/energy/motivation; concurrent zinc, vitamin D, magnesium and fish oil. A later 800 mg empty-stomach exposure reportedly caused vomiting.One short self-report with co-supplements and no objective outcome; higher exposure is an adverse anecdote, not a dosing precedent.
Exhaustive dump on why Tongkat Ali is causing me brain fog (opens in a new tab)OP and same-author replies read: historical 2%/10% use, early benefits followed by brain fog/joint pain around two weeks; 2026 re-exposure with strong energy then next-day brain fog for about two days; disclosed Wellbutrin, shilajit, DHEA, zinc, iodine, alpha-GPC, cistanche and boron, and later planned to stop Tongkat/cistanche.Retrospective, unblinded account with multiple products and medications; formulation history and causality uncertain.

What people say 14

Body-comp / training lore: Older training papers and forum stacks claim easier recomp or “drive”; replication, extract ID, and calorie control confounds are common. forum
vs TRT / Rx: Community frames tongkat as mild OTC support; clinical hypogonadism and fertility cases often escalate to medical TRT, SERMs, or fertility workups when labs stay low. forum
Expectation calibration: Responders often describe “noticeable but not steroid-like” libido/mood/T shifts; non-responders common when extract is weak or lifestyle is off. forum
Total testosterone (human): 2022 systematic review/meta-analysis of RCTs reported significant total-T improvement after *E. longifolia* as sole intervention, including healthy and hypogonadal-context men; effect size and extract identity vary by trial. trial
Aging men / borderline-low T: Multicenter RCT (Physta water extract, n=105, ages 50–70, baseline total T <300 ng/dL): 100 mg and 200 mg daily vs placebo for 12 weeks—total T rose vs placebo (200 mg significant from ~week 4; 100 mg by week 12); free T rose within-group; DHEA up from ~week 2; cortisol down mainly at 200 mg. trial
Late-onset hypogonadism / ADAM: Older LJ100-style arms (~200 mg/day) reported higher serum T and better Aging Males’ Symptom scores over roughly 1 month in LOH-context men. trial
Stress hormones & mood: Talbott et al. 2013—~200 mg/day standardized root extract for 4 weeks in moderately stressed adults: salivary cortisol exposure ~−16%, improved tension/anger/mood scores vs placebo. trial
Libido / sexual activity: Clinical + forum reports of improved desire and sexual frequency over weeks; Examine-style summaries often cite modest relative libido lifts over multi-week windows. trial
Erectile / sexual function endpoints: Some trials in sluggish/ADAM-context men report sexual-function score gains; sample sizes and extract brands differ. trial
Semen / fertility endpoints: Tambi et al. 2010—~200 mg/day proprietary standardized extract in idiopathic male infertility partners: improved semen volume, concentration, and motility over months; subset of couples later reported pregnancy (observational context, not large RCT proof). trial
Fatigue / QoL: Physta 200 mg arm associated with lower Fatigue Severity Scale and better AMS/QoL within about 2 weeks in the aging-male RCT narrative. trial
Muscle strength (secondary): Same aging-male RCT reported within-group strength gains by week 12 in Physta arms; primary endpoint was hormone/QoL, not elite performance. trial
Women / mixed-sex stress: Stress/mood arms included both sexes in some work; female libido/arousal talk appears in branded summaries—thinner dedicated female hormone RCTs than male T literature. trial
Animal HPG: Rodent models with quassinoid-rich extracts report spermatogenesis and T endpoints; used as mechanism support, not human dose maps. animal

Doses people talk about 16

Examine / guide band: Summaries commonly cite ~100–600 mg/day of extract depending on product concentration and goal (T vs sexual health often framed ~200–400 mg). forum
Eurycomanone math (community): Example: 200 mg of 2% eurycomanone ≈ 4 mg marker; 100 mg of 10% ≈ 10–12 mg marker—mg of raw extract is not interchangeable across % standards. forum
2% vs 10% eurycomanone debate: Full-spectrum ~2% (often 200 mg caps) closer to some trial-like exposures; high-marker 10% (often 100 mg caps) is discussed for potency but also for more stim/side risk at equal or higher marker load. forum
High/weak powder band: Threads sometimes list 800–1,600+ mg/day of unstandardized or low-ratio material—active delivery uncertain. forum
Timing: Morning or AM/PM split is common; evening avoided if wired, insomnia, or irritability. forum
With/without food: Often flexible; Physta protocol used after breakfast; empty-stomach GI complaints appear in minority logs. forum
Optional micro-cycle habit: Some guides/forums use 5 days on / 2 days off for tolerance—not a published gold-standard PK requirement. forum
Label math warning: 200 mg of 100:1 extract ≠ 200 mg raw root powder ≠ 200 mg of a different % eurycomanone product. forum
Quality flag: Third-party eurycomanone assay, heavy-metal screen, and root (not leaf/stem dump) identity matter more than marketing ratio. forum
Podcast/media band: Huberman-era talk frequently cites ~400 mg tongkat in the morning (personal/media dose, not a single unified RCT). forum
Vendor “step-up” talk: Some LJ100-style labels suggest start 100 mg, then 200–300 mg if tolerated; avoid exceeding ~400 mg/day without clinician input (vendor caution, not universal law). forum
Ratio-label products: 100:1 / 200:1 marketplace powders are common; forums stress that ratio alone without HPLC eurycomanone is a weak potency claim. forum
Core trial band: Most cited human arms use ~100–200 mg/day of standardized water extracts (LJ100 / Physta-style). trial
LJ100 / Physta standardization talk: Branded materials often claim ~1.5% eurycomanone class markers, ≥22% eurypeptides, ~40% glycosaponins (Physta: ~0.8–1.5% eurycomanone, ≥22% protein, ~30% polysaccharide, ~40% glycosaponin). trial
Framing: Ranges below are study and community discussion only—not medical advice, prescriptions, or personal protocols. forum
Physta RCT doses: 100 mg once daily after breakfast or 200 mg once daily after breakfast for 12 weeks (vs maltodextrin placebo). trial

How it may feel 8

Days 1–3: Accounts differ. One 400 mg/day 3% extract poster reported no clear effect on days 1–2 except diarrhea/nausea, then slight energy on day 3 and stronger libido/energy/motivation on days 4–5. That single short log cannot establish typical onset or prevalence. forum
Days 4–7: Still often flat; early libido “noise” is anecdotal and not reliable. forum
Weeks 1–2 and re-challenge reports: Human trials assess multi-week endpoints rather than a dependable same-day feeling. One detailed poster retrospectively described early benefits followed by brain fog and joint pain after roughly two weeks; on a later re-exposure they described strong energy followed the next day by brain fog lasting about two days. The report also disclosed Wellbutrin, shilajit, DHEA, zinc, iodine, alpha-GPC, cistanche and boron, so Tongkat-specific attribution is weak. anecdote
Weeks 4–8: Many bloodwork-curious users pull total/free T, SHBG, estradiol, CBC/CMP around here if stacking. forum
Month 3+: Continuous open-ended logs exist; long-term controlled safety at high gray-market doses is thinner than short trials. forum
No change ~4–6 weeks: Threads push extract identity (eurycomanone assay), sleep, calories, body fat, and baseline T—not automatic dose doubling. forum
Weeks 3–4: Common first real check-in for libido, mood, training motivation; Talbott stress study window is 4 weeks. trial
Weeks 8–12: Matches several published human arms (including Physta 12-week RCT); frequent “keep / drop / rebrand” decision point. trial

Cycles people discuss 9

Continuous daily: Many users run oral capsules daily with no formal off—especially when tolerating morning dosing well. forum
5 on / 2 off: Weekend-off pulse for sleep/mood tolerance—habit lore, not a standardized endocrine protocol. forum
3–4 weeks on / 1 week off: Alternate pulse used by side-sensitive users. forum
8–12 weeks then reassess: Matches common bloodwork and trial-length decision points. forum
Training camps: Some only run during contest prep or high-stress blocks. forum
Stacked with fadogia: When paired, users often adopt fadogia’s stricter on/off (e.g., 8–12 weeks on then off, or 3 on / 1 off) even if tongkat alone was continuous. forum
Study blocks: Published human arms often run ~4–12 weeks; some LOH/ADAM contexts up to ~6 months at ~200 mg/day. trial
Huberman-style framing: Media summaries often say tongkat need not be cycled as strictly as fadogia; some still use long on / short off habits. forum
Long-term gap: Short RCT tolerability ≠ multi-year high-dose multi-stack safety data for every extract strength. trial

Timing 8

Human PK gap: Reliable human plasma half-life for whole extract not established like a drug label—dosing is habit- and trial-schedule-based. forum
Why daily oral appears: Once-daily or split schedules come from trial designs, labels and user habit. A short rodent eurycomanone half-life does not by itself prescribe human whole-extract timing. forum
Downstream vs plasma: Multi-week endocrine, stress, and libido claims are adaptation/time-on-extract stories—not “drug still in blood all day.” anecdote
Practical timing: Morning preferred to spare sleep; meal co-timing not tightly standardized. forum
Marker PK (animal): The 0.30-hour estimate belongs to IV pure eurycomanone in rats and mice (Tables 1–2), not oral extract or human Tongkat use. animal
Oral bioavailability (animal): Low oral bioavailability in rats (~10–12% range in classic Low/Ahmad-line work); mice may absorb more (species-dependent; not human PK). animal
Tmax (animal): Oral peak around ~2 h post-dose in rat pure-eurycomanone work; secondary peaks discussed (enterohepatic or delayed emptying hypotheses). animal
Extract ≠ one molecule: Multiple quassinoids, peptides, saponins; one marker t½ ≠ full phytochemical blend kinetics. trial

Stacks 10

Tongkat + fadogia agrestis: Dominant podcast-era “natural T” duo; media examples often ~400 mg tongkat AM + ~400–600 mg fadogia with fadogia cycled harder. forum
Tongkat + ashwagandha: Stress + hormone crossover; cortisol/libido/sleep confounds large. forum
Minerals baseline: Boron (~2–4+ mg talk), zinc, magnesium, vitamin D often on free-T checklists—not proven obligatory synergy. forum
Tongkat + cistanche: Some nootropic/vendor communities pair them for “synergy” talk; human interaction data thin. forum
Tongkat + maca / fenugreek / tribulus: Classic male-vitality multi-herb blends; attribution gets noisy. forum
Tongkat + shilajit: Marketplace “test booster” formulas sometimes combine both. forum
+ Stimulants / pre-workout: Caffeine + tongkat increases restlessness/insomnia reports in stim-sensitive users. forum
vs Rx path: Compared in forums to enclomiphene/clomiphene or TRT when herbal stacks fail labs—different risk/evidence class. forum
Lifestyle co-stack: Sleep, progressive lifting, lower body fat, and calorie adequacy often credited when labs or libido look good. forum
Avoid megastacks for attribution: Running five “T boosters” at once makes side/benefit isolation impossible. forum

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 15

Stim / sleep: Insomnia, restlessness, wired feeling—especially high dose, high eurycomanone %, late-day dosing, or stim stacks. forum
Mood / irritability: Irritability, edginess, or “aggressive” feel reported in a minority; some LOH-context trial notes of irritability/sleep disturbance percentages in product write-ups. forum
Joint pain anecdotes: Minority long-term logs (including high-marker extracts) report joint discomfort—confounded and not a clean trial endpoint. anecdote
Hormone-sensitive conditions: Caution talk for prostate cancer, hormone-sensitive disease, and concurrent endocrine drugs—rodent T increases drive the theoretical concern. forum
Young eugonadal men: Forum reports of poor tolerance (wired, irritable, sleep loss) without clear benefit when baseline T is already solid. forum
Drug interactions: Limited formal interaction data; caution with other hormone, hepatotoxic, or stimulant agents is community-standard soft language. forum
Pregnancy / breastfeeding: Generally not discussed as appropriate research use in those populations in community caution lists. forum
GI: Nausea, abdominal discomfort, diarrhea, or gastric upset—among the more common mild complaints at conventional oral doses. trial
Headache / itch / rash: Headache; occasional pruritus or rash at conventional doses. trial
Liver injury signal: E. longifolia appeared among single-ingredient herbal products implicated in US DILI Network supplement hepatotoxicity series; cases often multi-ingredient/bodybuilding-context confounded—still a real caution. trial
EFSA / high-dose genotox note: High experimental water-extract exposures in animals raised DNA-damage concerns in GI tissues at very high mg/kg—not equivalent to typical 100–400 mg human capsules, but used in safety reviews. animal
Acute animal toxicity: Oral LD50-class work in mice for alcoholic extracts in the g/kg range; not a human dose chart. animal
Source / heavy metals: Historical Malaysian product survey found a subset with mercury above limits; gray-market identity risk remains. trial
Fertility context: Some clinical semen-parameter data are positive, but self-directed high-dose stacks are not a substitute for infertility workups. trial
Not risk-free: Short-trial lab safety ≠ long-term high-dose multi-stack guarantee; product quality dominates real-world risk. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 14

Doses people talk about 16

How it may feel 8

Cycles people discuss 9

Timing 8

More on what it is 6

Stacks 10

Storage notes 2

Related 8

Watch for 15

Timing context & sources